Marc Dunoyer Biography and Net Worth

CEO of Alexion & Chief Strategy Officer of AstraZeneca

Marc became CEO of Alexion, AstraZeneca’s Rare Disease group, in August 2021 following its acquisition in July. He had previously served as an Executive Director and AstraZeneca’s Chief Financial Officer from November 2013. Marc’s career in pharmaceuticals, which has included periods with Roussel Uclaf, Hoechst Marion Roussel and GSK, has given him extensive industry experience. He is a qualified accountant and joined AstraZeneca in 2013, serving as Executive Vice-President, Global Product and Portfolio Strategy from June to October 2013. Prior to that, he served as Global Head of Rare Diseases at GSK and (concurrently) Chairman, GSK Japan. He holds an MBA from HEC Paris and a Bachelor of Law degree from Paris University.

How do I contact Marc Dunoyer?: The corporate mailing address for Mr. Dunoyer and other AstraZeneca executives is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. AstraZeneca can also be reached via phone at 442037495000 and via email at [email protected]. Learn More on Marc Dunoyer's contact information.
Has Marc Dunoyer been buying or selling shares of AstraZeneca?: Marc Dunoyer has not been actively trading shares of AstraZeneca during the last ninety days. Learn More on Marc Dunoyer's trading history.
Who are AstraZeneca's active insiders?: AstraZeneca's insider roster includes Katarina Ageborg (EVP of Sustainability), Pam Cheng (EVP of Operations & Information Technology and Member of External Sustainability Advisory Board ), Marc Dunoyer (CEO of Alexion & Chief Strategy Officer ), Menelas Pangalos (EVP ), Aradhana Sarin (CFO & Exec. Director ), and Pascal Soriot (Executive Director and Chief Executive Officer ). Learn More on AstraZeneca's active insiders.

Marc Dunoyer Insider Trading History at AstraZeneca

Marc Dunoyer Buying and Selling Activity at AstraZeneca

AstraZeneca Company Overview

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Today's Range

Now: $65.99

$65.77

$66.41

50 Day Range

MA: $68.09

$63.20

$78.26

2 Week Range

Now: $65.99

$60.47

$87.68

Volume

2,874,059 shs

Average Volume

5,323,066 shs

Market Capitalization

$204.61 billion

P/E Ratio

31.57

Dividend Yield

1.50%

Beta

0.45

Trading 5-7 Stocks to Profit $1,300 a Day?

From Prosper Trading Academy | Ad

If you want a straightforward, faster, and potentially more reliable way to trade… Learn this strategy by watching this brand new video presentation

Click here to learn the 5-Stock Formula that could potentially boost your profit potential.